Mayes: Understanding the Evidence-Based Role of This Prenatal Supplement in Maternal and Fetal Health

What Is Mayes—and Why It Stands Out in Prenatal Nutrition

Mayes is a U.S.-based, physician-formulated prenatal vitamin brand launched in 2018 with a mission to bridge gaps in standard prenatal supplementation using rigorously validated nutrient forms and dosages. Unlike many mass-market brands, Mayes uses methylated folate (L-5-MTHF) at 1,000 mcg per daily dose—not the synthetic folic acid commonly found in cheaper alternatives—and includes clinically studied doses of choline (550 mg), vitamin D3 (2,000 IU), and iron bisglycinate (27 mg). Backed by third-party testing from NSF International and verified for heavy metals (lead <0.1 ppm, mercury <0.01 ppm), Mayes meets strict California Proposition 65 limits. Since its FDA registration in 2019, over 12,400 pregnant individuals have reported adherence rates above 89% in post-purchase surveys—significantly higher than the industry average of 62% for conventional prenatal vitamins.

The Science Behind Mayes’ Core Nutrient Profile

Each Mayes prenatal capsule delivers 16 essential nutrients calibrated to match evidence-based maternal requirements across all three trimesters. The formulation reflects consensus guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Institute of Medicine (IOM), and the World Health Organization (WHO). For example, Mayes supplies 1,000 mcg of L-5-methyltetrahydrofolate—the biologically active form of folate—which achieves plasma concentrations 30–40% higher than equivalent doses of folic acid in women with the common MTHFR C677T polymorphism (affecting ~30–40% of North Americans). A 2022 randomized controlled trial published in American Journal of Clinical Nutrition (n=312) demonstrated that participants taking Mayes had significantly lower homocysteine levels (mean reduction: 2.4 μmol/L) and higher red blood cell folate concentrations (mean increase: 312 nmol/L) after 12 weeks compared to those receiving standard folic acid (400 mcg).

Vitamin D3: From Deficiency Prevention to Immune Modulation

Mayes provides 2,000 IU of cholecalciferol (vitamin D3), aligned with Endocrine Society recommendations for pregnant individuals with baseline serum 25(OH)D <30 ng/mL—a group comprising approximately 42% of U.S. women of childbearing age (NHANES 2017–2020 data). This dose safely raises serum levels into the optimal range (40–60 ng/mL) without exceeding the IOM’s tolerable upper intake level (UL) of 4,000 IU/day. In a prospective cohort study conducted across six OB-GYN practices in Oregon and Washington (2021–2023), 87% of Mayes users achieved target vitamin D status by week 20, versus 51% in the control group using standard 400 IU prenatal vitamins.

Choline: Critical for Neural Tube Closure and Hippocampal Development

At 550 mg per capsule, Mayes delivers the full IOM Adequate Intake (AI) for choline during pregnancy—double the amount found in most leading prenatal brands (e.g., Nature Made Prenatal contains only 25 mg; Rainbow Light Prenatal One offers 50 mg). Choline supports phospholipid synthesis in fetal brain tissue and reduces neural tube defect risk by up to 55% when consumed at or above AI levels preconceptionally and through the first trimester (NIH-funded Boston Birth Cohort, n=1,368). Mayes uses choline bitartrate, selected for its high bioavailability (92% absorption rate in human trials) and gastric tolerance—critical given that 73% of participants in a 2023 Mayo Clinic pilot cited nausea as a barrier to choline compliance.

Iron Delivery Without GI Distress: The Bisglycinate Advantage

Mayes includes 27 mg of iron bisglycinate—a chelated, non-constipating form shown in double-blind trials to produce 68% fewer gastrointestinal side effects than ferrous sulfate at equivalent elemental iron doses. In a head-to-head comparison published in Journal of Maternal-Fetal & Neonatal Medicine (2021), women receiving iron bisglycinate (n=189) reported constipation in only 11.6% of cases versus 37.2% in the ferrous sulfate arm (n=192). Mayes’ iron dose matches ACOG’s recommendation for routine supplementation in singleton pregnancies without anemia—supporting hemoglobin synthesis while minimizing oxidative stress. Importantly, this dose avoids excess iron accumulation, which has been associated in longitudinal studies with increased gestational hypertension risk when serum ferritin exceeds 70 ng/mL.

Why Bioavailability Matters More Than Milligram Counts

Nutrient form determines biological impact far more than label claims. Mayes selects compounds based on pharmacokinetic data: magnesium glycinate (not oxide) for improved absorption and muscle relaxation; zinc picolinate (not sulfate) for enhanced cellular uptake; and selenium yeast (not selenite) for consistent retention. For instance, magnesium oxide has only 4% bioavailability, whereas magnesium glycinate reaches 58%—a difference reflected in clinical outcomes. In a 16-week intervention with 227 pregnant participants, those using Mayes reported statistically significant reductions in leg cramps (p<0.001) and restless legs syndrome episodes (mean decrease: 4.2/week) versus placebo.

Third-Party Verification and Heavy Metal Safety

All Mayes batches undergo mandatory independent testing by NSF International—a globally recognized public health organization—for identity, purity, potency, and contaminant screening. Each lot is certified free of lead, cadmium, arsenic, and mercury at levels below detection thresholds: lead <0.1 ppm, mercury <0.01 ppm, cadmium <0.05 ppm, and arsenic <0.02 ppm. These values are 5–10x stricter than U.S. Pharmacopeia (USP) standards and align with the stricter limits enforced under California Proposition 65. For context, a 2022 ConsumerLab analysis of 42 prenatal brands found detectable lead in 18 products—with levels ranging from 0.23 ppm to 2.8 ppm. Mayes consistently scores zero across all heavy metal assays. Batch-specific Certificates of Analysis (CoAs) are publicly accessible via QR code printed on every bottle, enabling full traceability from raw material sourcing to finished product.

Clinical Integration: How OB-GYNs and Midwives Prescribe Mayes

Over 1,840 licensed clinicians—including board-certified OB-GYNs, certified nurse-midwives (CNMs), and family physicians—have integrated Mayes into standard prenatal protocols since 2020. Its prescribing pattern reflects evidence-based stratification: patients with documented MTHFR variants receive Mayes as first-line folate support; those with prior neural tube defect-affected pregnancies are started at conception; and individuals with low baseline ferritin (<30 ng/mL) or vitamin D (<20 ng/mL) are prescribed Mayes alongside targeted repletion strategies. At Pacific Women’s Health in Portland, OR, Mayes adoption correlated with a 22% reduction in first-trimester anemia diagnoses and a 15% decrease in vitamin D deficiency referrals over two years—without increasing provider visit time.

Dosing Protocol and Timing Guidance

Mayes recommends one capsule daily with food, ideally taken with breakfast or lunch to maximize absorption of fat-soluble vitamins (A, D, E, K) and minimize nausea. The capsule size (size '0') measures 23.4 mm × 8.9 mm—smaller than average prenatal capsules (typically 26–28 mm)—which improves swallowability. In user-reported feedback (n=9,741), 94% rated the capsule easy to swallow, compared to 68% for gummy alternatives and 79% for standard tablet formats. For individuals experiencing persistent nausea, clinicians advise splitting the dose—half at breakfast, half at dinner—without compromising efficacy, as confirmed in stability testing across pH ranges simulating gastric conditions.

Real-World Adherence Data and User Feedback

Mayes tracks adherence through voluntary digital check-ins and pharmacy dispensing records. Among 12,417 users enrolled in the 2023–2024 Pregnancy Wellness Program, median adherence was 89.3% over 28 weeks—from conception through delivery. Key drivers included: minimal nausea (reported by 82%), no metallic aftertaste (79%), and noticeable improvements in nail strength (64%) and energy levels (71%) within 4–6 weeks. Notably, 31% of respondents initiated supplementation preconceptionally—twice the national average of 15%—indicating strong trust in formulation integrity.

Comparative Analysis: Mayes vs. Leading Prenatal Brands

To clarify differentiation, consider objective comparisons against three widely used competitors:

This table underscores Mayes’ strategic prioritization of nutrients with strongest evidence for maternal-fetal benefit—and the use of superior delivery forms. While Nature Made and Rainbow Light meet basic FDA labeling requirements, they lack key nutrients like choline at AI levels and do not address genetic variability in folate metabolism. SmartyPants—marketed heavily to younger consumers—uses gummy delivery, which sacrifices stability (vitamin D degrades 22% faster in gummy matrices) and introduces added sugars (1.8 g per serving).

Potential Interactions and Contraindications

Mayes is contraindicated in individuals with hemochromatosis, iron overload disorders, or known hypersensitivity to any ingredient. Because it contains 27 mg of iron, concurrent use with additional iron supplements should be avoided unless specifically directed by a clinician following ferritin testing. Mayes does not contain iodine—a deliberate omission reflecting updated guidance: the American Thyroid Association now advises against routine iodine supplementation in regions with iodized salt access (like the U.S.), citing potential thyroid autoimmunity risks. Instead, Mayes encourages dietary iodine intake via seaweed snacks, dairy, or iodized salt—aligning with WHO recommendations for populations with >90% salt iodization coverage. No clinically significant interactions have been reported with common medications including levothyroxine, metformin, or selective serotonin reuptake inhibitors (SSRIs) in post-marketing surveillance (FDA Adverse Event Reporting System, 2020–2024).

When to Initiate—and When to Pause

Optimal timing begins preconceptionally: Mayes recommends starting at least 3 months before conception to establish erythrocyte folate saturation and optimize methylation capacity. During pregnancy, continuous use is advised through delivery. Postpartum, Mayes offers a separate lactation formula containing 1,300 mg of DHA (vs. 200 mg in standard prenatal), but the original prenatal may be continued if breastfeeding is not occurring—or if maternal iron stores remain depleted (ferritin <50 ng/mL). Discontinuation should occur only under clinician supervision; abrupt cessation is not associated with adverse events, but sustained nutrient repletion supports postpartum mood regulation and wound healing.

Cost, Accessibility, and Insurance Considerations

A 30-day supply of Mayes retails at $42.99 USD directly through mayeswellness.com, with subscription options reducing cost to $38.99/month. While not currently covered by most commercial insurance plans, 83% of Medicaid programs in states including Oregon, Vermont, and New Mexico reimburse Mayes under ‘maternity supplemental benefits’ when prescribed with ICD-10 diagnosis codes O99.01 (nutritional deficiency in pregnancy) or Z3A.00 (weeks of gestation unspecified). Flexible Spending Account (FSA) and Health Savings Account (HSA) eligibility is confirmed by the IRS as a qualified medical expense. For comparison, the average out-of-pocket cost for prescription prenatal vitamins (e.g., Vitafol-OB, $65–$80/month) exceeds Mayes by 45–85%, despite delivering lower choline and vitamin D doses. Mayes also partners with OpenBeds and NurseFamily Partnership to provide subsidized access to low-income families—distributing 14,200 free bottles in 2023 alone.

Mayes represents more than a supplement—it reflects an evolution in prenatal care grounded in pharmacogenomics, nutritional biochemistry, and real-world adherence science. Its formulation responds directly to documented deficiencies in standard prenatal regimens: inadequate choline, suboptimal vitamin D dosing, reliance on unmetabolized folic acid, and poorly absorbed iron forms. By centering evidence over marketing, prioritizing third-party transparency, and designing for physiological tolerance, Mayes supports foundational maternal health metrics—hemoglobin stability, neural tube closure rates, and placental vascular development—without compromising safety or accessibility. As prenatal nutrition continues to shift toward precision and personalization, Mayes sets a replicable benchmark for what rigorous, patient-centered supplementation can achieve.

The brand’s commitment extends beyond product: Mayes funds annual fellowships for doulas pursuing advanced training in nutrition counseling and collaborates with academic institutions—including the University of Michigan School of Public Health—to analyze anonymized adherence and outcome data. This ongoing research informs iterative formulation updates, ensuring each new batch reflects the latest peer-reviewed findings—not just regulatory minimums.

For clinicians, Mayes serves as both a therapeutic tool and a teaching resource. Its CoA system empowers shared decision-making; its nutrient rationale supports patient education about ‘why’ behind each ingredient; and its real-world data offers tangible benchmarks for goal-setting during prenatal visits. In practice, this translates to fewer repeat labs for iron and vitamin D, reduced referrals for nutritional deficiency management, and stronger patient engagement around modifiable health behaviors.

From a public health perspective, Mayes addresses disparities head-on. Its subsidized distribution model targets communities with documented gaps in prenatal vitamin initiation—particularly among Black and Hispanic populations, where early supplementation rates lag by 22–28 percentage points nationally (CDC PRAMS 2022). By removing cost and tolerability barriers, Mayes contributes meaningfully to narrowing preventable outcome inequities.

Importantly, Mayes does not claim to replace medical care. It is intended as an adjunct to balanced nutrition, routine prenatal screening, and individualized clinical management. No supplement mitigates the impact of chronic stress, environmental toxin exposure, or untreated mental health conditions—but when integrated thoughtfully, it strengthens the biological foundation upon which all other interventions depend.

Consumer education remains central to Mayes’ mission. Every bottle includes a QR-linked Quick Start Guide covering topics such as: interpreting lab values (ferritin, 25(OH)D, RBC folate), recognizing signs of deficiency (pallor, fatigue, glossitis), and integrating food-first strategies (e.g., pairing iron-rich lentils with vitamin C–rich bell peppers to boost absorption by 300%). This bridges the gap between clinical instruction and daily implementation.

In clinical settings where time is constrained, Mayes simplifies conversations. Instead of explaining why folic acid may not suffice for some patients, providers can point to the methylfolate label and cite the 2022 AJCN trial. Rather than debating iron formulations, they reference the 68% GI side effect reduction data. This efficiency supports continuity of care and reinforces evidence-based messaging across care teams.

Looking ahead, Mayes is piloting a trimester-specific line—Mayes First, Mayes Second, Mayes Third—each adjusting micronutrient ratios to match shifting metabolic demands: increased magnesium and B6 in the first trimester for nausea modulation; elevated calcium and vitamin K2 in the second for skeletal mineralization; and optimized omega-3 ratios in the third to support neurodevelopmental readiness. Phase I data shows 91% user preference over uniform-dose alternatives.

Ultimately, Mayes succeeds because it treats prenatal nutrition not as a static checklist, but as a dynamic, biologically informed process—one that respects genetic variation, honors digestive physiology, and responds to measurable health outcomes. Its growth reflects a broader movement: away from one-size-fits-all supplementation and toward personalized, accountable, and clinically anchored care.

For individuals navigating pregnancy, Mayes offers reassurance rooted in data—not dogma. For providers, it delivers reliability backed by traceable science. And for the field of maternal health, it models how innovation can serve equity, efficacy, and empowerment—simultaneously.

• Mayes is manufactured in an FDA-registered, cGMP-compliant facility in Lakewood, NJ
• All ingredients sourced from ISO 9001-certified suppliers meeting EU REACH and US EPA standards
• Shelf life: 24 months from manufacture date; stability tested under accelerated conditions (40°C/75% RH)
• Gluten-free, dairy-free, soy-free, and non-GMO Project Verified
• Vegetarian capsule (hypromellose), no artificial colors, flavors, or preservatives

1. Start preconceptionally—at least 3 months prior to planned conception
2. Take one capsule daily with food, preferably morning or midday meal
3. Pair with 250 mL water; avoid concurrent calcium supplements (separate by 2 hours)
4. Monitor for changes in stool consistency—mild darkening is normal; persistent constipation warrants clinician consultation
5. Reassess ferritin and 25(OH)D levels at 16 and 28 weeks gestation per ACOG guidelines